VYGR (Voyager Therapeutics) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VYGR Voyager Therapeutics Inc VYGR
52 GF Score
Price $3.25
GF Value $1.66
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Voyager Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

VYGR
52GF Score
Voyager Therapeutics Inc VYGR
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Voyager Therapeutics (VYGR) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of $3.25 is trading 95.5% above its estimated GF Value™ of $1.66. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for VYGR:

  • FFO:
  • GF Value™: $1.66 vs. price of $3.25 (95.5% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the VYGR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:MexicoVT6:Germany
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
52GF Score

Get the complete analysis for VYGR

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25
Price
$1.66
GF Value